Mark SOMMERFELD,Thomas LANGER,Oliver BOSCHEINEN,Matthias DREYER,Werner DITTRICH,Paul HABERMANN
申请号：
US15776726
公开号：
US20180371041A1
申请日:
2016.12.02
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.
